Skip to main content
. 2013 Feb 13;38(7):1308–1321. doi: 10.1038/npp.2013.29

Figure 4.

Figure 4

DHPG-induced I-LTD requires the activation of ERK1/2 and mTOR signaling pathways. (a) The MEK inhibitor U0126 (20 μM) exerted only a modest effect on DHPG-induced I-LTD that did not reach statistical significance (n=8, p>0.05 vs control). U0124 (20 μM), an inactive analog of U0126, had no effect on DHPG I-LTD (n=7, p>0.05 vs control). (b) The mTOR inhibitor rapamycin (Rapa, 100 nM) also had no significant effect on DHPG-induced I-LTD (n=7, p>0.05 vs control), whereas co-application of rapamycin (100 nM) and U0126 (20 μM) blocked DHPG-induced I-LTD (n=8, p<0.05 vs control). Error bars indicate SEM.